Yong-Ding Wu

Yong-Ding Wu

Auto-generated profile, based on publicly available information

Yong-Ding Wu

Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2025 in Drug Resistance Updates
Verified
Journal Article
Open access
HLHongyi Lin
Hongyi Lin
SZShuncang Zhu
Shuncang Zhu
YCYinhao Chen
Yinhao Chen
JLJinpeng Lu
Jinpeng Lu
CXChengke Xie
Chengke Xie
SCShi Chen
Shi Chen
Current therapeutic strategies for pancreatic ductal adenocarcinoma (PDAC) have limited efficacy in increasing patient survival rates, largely due to ferroptosis resistance and immunosuppression. The aim of this study is to identify molecular mechanisms associated with ferroptosis resistance and immunosuppression in PDAC tumour cells. Circular RNA sequencing (circRNA-seq) was performed on clinical samples to identify potential circRNAs that mediate ferroptosis resistance. C11-BODIPY staining, FerroOrange staining, the glutathione ratio, malondialdehyde quantification, and transmission electron microscopy were employed to assess ferroptosis. RNA pulldown, mass spectrometry, RNA immunoprecipitation, and coimmunoprecipitation assays were conducted to investigate the molecular mechanisms involved. A HuNSG mouse xenograft tumour model was utilized to validate therapeutic agents. A circRNA derived from TRIP12 (cTRIP12) was identified in PDAC samples resistant to ferroptosis. cTRIP12 knockdown increased the sensitivity of PDAC cells to ferroptosis and immunotherapy. Subsequent mechanistic studies revealed that cTRIP12 specifically binds to the O-linked N-acetylglucosamine transferase (OGT) protein and increases intracellular O-GlcNAcylation levels, leading to increased protein levels of ferritin heavy chain (FTH) and PD-L1 in tumour cells. Notably, high cTRIP12 expression suppressed ferroptosis sensitivity and increased immune resistance in PDAC cells by functioning as a protein scaffold through its interaction with OGT and protein kinase R-like endoplasmic reticulum kinase (PERK). cTRIP12 inhibition induced ferroptosis in PDAC cells by reducing FTH and PD-L1 expression and synergistically increased the immunotherapy efficacy. In vivo animal experiments confirmed that the triple therapy consisting of GSK2656157, erastin, and anti-CTLA-4 effectively suppressed the progression of PDAC in tumours with high cTRIP12 expression. We elucidated the molecular mechanisms underlying the simultaneous occurrence of ferroptosis resistance and immune suppression in PDAC patients. Our study provides a novel therapeutic strategy that could promote ferroptosis in tumour cells and increase immunotherapy efficacy.

22 November 2025 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
XHXiao-Xiao Huang
Xiao-Xiao Huang
CXCheng-Ke Xie
Cheng-Ke Xie
YMYi-Chao Mo
Yi-Chao Mo
WLWei Li
Wei Li
YWYong-Ding Wu
Yong-Ding Wu
SCShi Chen
Shi Chen
Cuproptosis, a newly identified form of cell death, is closely linked to copper homeostasis and protein lipoylation. Using a multi-omics approach, we firstly reveal that SERPINB3 confers cuproptosis resistance in pancreatic cancer and functions as a theranostic biomarker. Mechanistically, SERPINB3 inhibits FDX1 transcription by activating the MAPK signaling pathway, thereby conferring cuproptosis resistance. We further demonstrated that SERPINB3 directly interacts with MEK1, impeding its chaperone-mediated autophagic degradation, which ultimately leads to sustained activation of the MAPK signaling pathway. Additionally, we found that SERPINB3 promotes pancreatic cancer immune evasion by upregulating PD-L1 expression on tumor cells. This phenomenon motivated the development of a triple-combination strategy consisting of MAPK inhibition, cuproptosis induction, and αPD-1 therapy for pancreatic cancer patients with high SERPINB3 expression. To this end, we further developed a metal-organic framework (MOF) loaded with both copper ions and MEK inhibitor, which significantly triggers tumor-specific cuproptosis and enhances antitumor immunity. In summary, SERPINB3 serves as a predictive biomarker to inform therapeutic strategies targeting cuproptosis, thereby establishing a novel paradigm for cancer immunotherapy that integrates metal biology, targeted therapy, and immune modulation.

30 June 2025 in Cancer Research
Verified
Journal Article
Closed access
YWYong-Ding Wu
Yong-Ding Wu
XHXiao-Xiao Huang
Xiao-Xiao Huang
HZHao-Xiang Zhang
Hao-Xiang Zhang
YPyu pan
yu pan
CXCheng-Ke Xie
Cheng-Ke Xie
SCShi Chen
Shi Chen
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies. PDAC is characterized by prominent necrotic foci within the tumor and a high propensity for distant liver metastasis, leading to a poor prognosis. In this study, using patient-derived organoid models, single-cell RNA sequencing, and multiplex immunofluorescence staining of samples from patients with PDAC, in vivo TGFβ1 conditional knockout mouse models, and 3D in vitro models, we discovered that the formation of intratumoral necrotic foci in pancreatic cancer is closely associated with liver metastatic events. This process was triggered by the deficiency of the long noncoding RNA TRAF3IP2-AS1 that induced necroptosis, which was accompanied by an immunosuppressive microenvironment. Mechanistically, TRAF3IP2-AS1 blocked necroptosis by reducing the mRNA stability of MLKL through competitively binding to IGF2BP2. Loss of TRAF3IP2-AS1 also promoted necroptosis by promoting RIPK3 phosphorylation via interference with the ubiquitination of the phosphatase PPM1B that dephosphorylates RIPK3. Additionally, TRAF3IP2-AS1 deficiency promoted the release of TGFβ1 from tumor cells, which induced an M2-like immunosuppressive phenotype and the release of more TGFβ1. The elevated production of TGFβ1 created a feedback loop that promoted the transcription of TRAF3IP2-AS1 in tumor cells to balance necroptosis. Overall, these findings identify TRAF3IP2-AS1 as a key regulator of necroptosis and the formation of an immunosuppressive microenvironment in PDAC, providing potential therapeutic targets for treating liver metastasis in patients with pancreatic cancer. Significance: TRAF3IP2-AS1 deficiency drives necroptosis in pancreatic cancer cells to engender a prometastatic immunosuppressive niche mediated by TGFβ1 production, providing mechanistic understanding of necroptosis and therapeutic strategies for treating liver metastasis.

2 September 2025
Verified
Other
Open access
PDF file
YWYong-Ding Wu
Yong-Ding Wu
XHXiao-Xiao Huang
Xiao-Xiao Huang
HZHao-Xiang Zhang
Hao-Xiang Zhang
YPyu pan
yu pan
CXCheng-Ke Xie
Cheng-Ke Xie
SCShi Chen
Shi Chen
Supplementary Fig. S8 TRAF3IP2-AS1 deficiency induces necroptosis in human PDAC through the synergistic action of IGF2BP2 and PPM1B

2 September 2025
Verified
Other
Open access
PDF file
YWYong-Ding Wu
Yong-Ding Wu
XHXiao-Xiao Huang
Xiao-Xiao Huang
HZHao-Xiang Zhang
Hao-Xiang Zhang
YPyu pan
yu pan
CXCheng-Ke Xie
Cheng-Ke Xie
SCShi Chen
Shi Chen
Supplementary Table S2 Characteristics of the organoids in the In-House Cohort

2 September 2025
Verified
Other
Open access
PDF file
YWYong-Ding Wu
Yong-Ding Wu
XHXiao-Xiao Huang
Xiao-Xiao Huang
HZHao-Xiang Zhang
Hao-Xiang Zhang
YPyu pan
yu pan
CXCheng-Ke Xie
Cheng-Ke Xie
SCShi Chen
Shi Chen
Supplementary Fig. S3 TRAF3IP2-AS1 deficiency leads to necroptosis in PDAC.